Idiopathic pulmonary fibrosis (IPF) is an idiopathic interstitial pneumonia with poor survival and poor prognosis. But, there are very limited clinical treatments for the disease. In 2011, the American Thoracic Society (ATS), the European Respiratory Society (ERS), the Japanese Respiratory Society (JRS) and the Latin American Thoracic Society (ALAT) published idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management, and provided treatment proposals. But afterwards, the results of some clinical trials were in conflict with the recommendations in the 2011 guideline. In 2015, the agency issued an update of the 2011 clinical practice guideline. In this paper, we reviewed the drugs for the treatment of IPF in the guidelines in 2011, and the recommendations for each drug in the 2015 update.